I’m excited to share the 360 Skin Sculpting Device Cryolipolysis with you. As a forward-thinking Company, we know clinics want High-Quality equipment that delivers reliable results and easy operation. This device uses advanced cryolipolysis tech to target fat cells precisely, while protecting surrounding tissue. With an ergonomic handpiece, adjustable cooling, and smart safety sensors, sessions are comfortable and safe for patients. The treatment is fast, with short cycle times, so you can treat more clients per day and improve ROI. We designed it to be dust-free maintenance and simple software updates, making service calls rare. Training and after-sales support are included, so your team can hit the ground running. It’s compact enough for modern clinics, yet robust enough for busy centers. If you’re seeking a High-Quality, dependable solution, this 360 Skin Sculpting Device Cryolipolysis could be the right fit for your portfolio.
Global buyers seek safe, effective body contouring solutions for markets with varied regulations. A 360 skin sculpting platform powered by cryolipolysis blends precise cooling with ergonomic applicators to deliver targeted fat reduction across multiple zones. The 2025 shift toward custom solutions favors modular heads, scalable software, and configurable treatment protocols that fit local workflows. With intuitive interfaces, multilingual support, and compliant documentation, clinics minimize downtime and boost throughput. From a procurement perspective, true value combines safety, compliance, serviceability, and total cost of ownership. Look for rigorous QA, ISO standards, and robust traceability. A 2025 solution should offer flexible manufacturing options (OEM/ODM), predictable lead times, modular spares, and training programs. Remote diagnostics, software updates, and long-term parts support reduce geographic risk, enabling a globally supported supply chain with consistent outcomes across markets.
| Device_ID | Region | Study_Type | Year | Sample_Size | Target_Area | Treatment_Session_Length_min | Temperature_C | Efficacy_Rate_percent | Adverse_Events_Rate_percent | Patient_Age_Range | Certification_Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D-360C01 | North America | Clinical Trial | 2021 | 40 | Abdomen | 30 | -8 | 24 | 2.5 | 25-45 | FDA_Approved |
| D-360C02 | Europe | Observational | 2022 | 82 | Flanks | 35 | -9 | 26 | 1.8 | 30-50 | CE_Mark |
| D-360C03 | Asia-Pacific | Pilot Study | 2023 | 120 | Submental | 28 | -8 | 22 | 0.9 | 28-55 | CE_Mark |
| D-360C04 | Europe | Randomized Controlled Trial | 2024 | 55 | Thighs | 32 | -7 | 28 | 3.5 | 24-44 | FDA_Approved |
| D-360C05 | Latin America | Post-market Surveillance | 2025 | 300 | Abdomen and Flanks | 40 | -6 | 30 | 1.0 | 25-60 | CE_Mark |
| D-360C06 | Africa | Comparative Study | 2023 | 150 | Arms | 25 | -9 | 18 | 2.7 | 20-40 | Not_Approved |